About this Journal Submit a Manuscript Table of Contents
Cholesterol
Volume 2013 (2013), Article ID 502948, 6 pages
http://dx.doi.org/10.1155/2013/502948
Research Article

Discordance of Non-HDL and Directly Measured LDL Cholesterol: Which Lipid Measure is Preferred When Calculated LDL Is Inaccurate?

1James J. Peters VA Medical Center, Bronx, NY 10468, USA
2Mt. Sinai School of Medicine, NY, USA
3Confluence Health, Moses Lake, WA 98837, USA
4St. Luke’s Hospital, University of Missouri, Kansas City, MO 64111, USA

Received 12 February 2013; Accepted 25 March 2013

Academic Editor: Gerhard M. Kostner

Copyright © 2013 Lawrence Baruch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. I. Cleeman, “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at Scopus
  2. R. McPherson, J. Frohlich, G. Fodor, and J. Genest, “Canadian Cardiovascular Society position statement—recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease,” Canadian Journal of Cardiology, vol. 22, no. 11, pp. 913–927, 2006. View at Scopus
  3. S. M. Grundy, J. I. Cleeman, C. N. Merz, et al., “National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines,” Circulation, vol. 110, pp. 227–239, 2004.
  4. L. Baruch, S. Agarwal, B. Gupta et al., “Is directly measured low-density lipoprotein clinically equivalent to calculated low-density lipoprotein?” Journal of clinical lipidology, vol. 4, no. 4, pp. 259–264, 2010. View at Scopus
  5. K. A. Foley, R. J. Simpson, J. R. Crouse, T. W. Weiss, L. E. Markson, and C. M. Alexander, “Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events,” American Journal of Cardiology, vol. 92, no. 1, pp. 79–81, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. J. J. Kastelein, W. A. van der Steeg, I. Holme, et al., “Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment,” Circulation, vol. 117, pp. 3002–3009, 2008.
  7. P. M. Ridker, N. Rifai, N. R. Cook, G. Bradwin, and J. E. Buring, “Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women,” Journal of the American Medical Association, vol. 294, no. 3, pp. 326–333, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Pischon, C. J. Girman, F. M. Sacks, N. Rifai, M. J. Stampfer, and E. B. Rimm, “Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men,” Circulation, vol. 112, no. 22, pp. 3375–3383, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Cui, R. S. Blumenthal, J. A. Flaws, et al., “Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality,” Archives of Internal Medicine, vol. 161, pp. 1413–1419, 2001.
  10. B. J. Arsenault, J. S. Rana, E. S. G. Stroes et al., “Beyond low-density lipoprotein cholesterol. Respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women,” Journal of the American College of Cardiology, vol. 55, no. 1, pp. 35–41, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. G. Robinson, S. Wang, B. J. Smith, and T. A. Jacobson, “Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk,” Journal of the American College of Cardiology, vol. 53, no. 4, pp. 316–322, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. M. J. Blaha, R. S. Blumenthal, E. A. Brinton, and T. A. Jacobson, “The importance of non-HDL cholesterol reporting in lipid management,” Journal of Clinical Lipidology, vol. 2, no. 4, pp. 267–273, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J. D. Brunzell, M. Davidson, C. D. Furberg et al., “Lipoprotein management in patients with cardiometabolic risk. Consensus conference report from the american diabetes association and the american college of cardiology foundation,” Journal of the American College of Cardiology, vol. 51, no. 15, pp. 1512–1524, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. J. H. Contois, J. P. McConnell, A. A. Sethi et al., “Apolipoprotein B and cardiovascular disease risk: position statement from the AACC lipoproteins and vascular diseases division working group on best practices,” Clinical Chemistry, vol. 55, no. 3, pp. 407–419, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. M. H. Davidson, C. M. Ballantyne, T. A. Jacobson, et al., “Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists,” Journal of Clinical Lipidology, vol. 5, pp. 338–567, 2011.
  16. S. M. Boekholdt, B. J. Arsenault, S. Mora, et al., “Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis,” The Journal of the American Medical Association, vol. 307, pp. 1302–1309, 2012.